Kuvan
About Kuvan
Provider of prescription medication for phenylketonuria (PKU). This medication is used to lower blood Phe levels in adults and children over one month of age with a specific type of PKU, in conjunction with a Phe-restricted diet. The medication offers various dosage forms and is supported by resources including clinical coordinators and educational materials. It addresses the management of PKU through a combination of pharmaceutical intervention and dietary control. The company also provides a trial program for eligible patients. Important safety information and potential side effects are clearly communicated.
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
BioMarin Pharmaceutical
(Dec 18, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kuvan
Detailed funding history for Kuvan
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Kuvan
Kuvan has secured backing from 1 investor. Prominent investors backing the company include BioMarin Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
Locked | Locked | Locked |
Investor details for Kuvan
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kuvan
Investment portfolio details for Kuvan
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kuvan
Detailed financials for Kuvan
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kuvan Comparisons
Peer comparison for Kuvan
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kuvan
Detailed competitors of Kuvan
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kuvan
Complete news archive for Kuvan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kuvan
Provider of prescription medication for phenylketonuria (PKU). This medication is used to lower blood Phe levels in adults and children over one month of age with a specific type of PKU, in conjunction with a Phe-restricted diet. The medication offers various dosage forms and is supported by resources including clinical coordinators and educational materials. It addresses the management of PKU through a combination of pharmaceutical intervention and dietary control. The company also provides a trial program for eligible patients. Important safety information and potential side effects are clearly communicated.
Kuvan has 1 investor. Key investors include BioMarin Pharmaceutical.